STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 98 filers reported holding STOKE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.14 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $313,325 | -66.1% | 79,524 | -8.5% | 0.00% | -66.7% |
Q2 2023 | $923,439 | +62.6% | 86,871 | +27.4% | 0.00% | +50.0% |
Q1 2023 | $568,064 | +38.8% | 68,195 | +53.8% | 0.00% | +100.0% |
Q4 2022 | $409,304 | +108.8% | 44,345 | +191.2% | 0.00% | 0.0% |
Q3 2022 | $196,000 | +4.3% | 15,230 | +6.8% | 0.00% | – |
Q2 2022 | $188,000 | -77.7% | 14,259 | -64.4% | 0.00% | -100.0% |
Q1 2022 | $842,000 | +102.9% | 40,000 | +131.2% | 0.00% | +100.0% |
Q4 2021 | $415,000 | -5.7% | 17,300 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $440,000 | -24.4% | 17,300 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $582,000 | -13.4% | 17,300 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $672,000 | -37.3% | 17,300 | 0.0% | 0.00% | -50.0% |
Q4 2020 | $1,071,000 | +64.0% | 17,300 | -11.3% | 0.00% | 0.0% |
Q3 2020 | $653,000 | +40.4% | 19,500 | 0.0% | 0.00% | +100.0% |
Q2 2020 | $465,000 | +44.0% | 19,500 | +38.3% | 0.00% | 0.0% |
Q1 2020 | $323,000 | -18.0% | 14,100 | +1.4% | 0.00% | 0.0% |
Q4 2019 | $394,000 | +31.8% | 13,900 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $299,000 | – | 13,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |